Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype
✱ These authors have contributed equally to this work.
Language :
English
Title :
Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. DOI: 10.3389/fmicb.2012.00388
Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322. DOI: 10.3389/fmicb.2012.00322
Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428–37. DOI: 10.1111/j.1365-2141.1991.tb08051.x
Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570–7. DOI: 10.1182/blood-2015-03-632489
Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised Adult T-Cell leukemia-lymphoma international consensus meeting report. J Clin Oncol J Am Soc Clin Oncol. 2019;37:677–87. DOI: 10.1200/JCO.18.00501
Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337–43. DOI: 10.1182/blood-2009-09-242347
Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J-I, et al. Integrated molecular analysis of adult T-cell leukemia/lymphoma. Nat Genet. 2015;47:1304–15. DOI: 10.1038/ng.3415
Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol J Am Soc Clin Oncol. 2009;27:453–9. DOI: 10.1200/JCO.2008.18.2428
Yamada Y, Hatta Y, Murata K, Sugawara K, Ikeda S, Mine M, et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol J Am Soc Clin Oncol. 1997;15:1778–85. DOI: 10.1200/JCO.1997.15.5.1778
Nosaka K, Maeda M, Tamiya S, Sakai T, Mitsuya H, Matsuoka M. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res. 2000;60:1043–8.
Tawara M, Hogerzeil SJ, Yamada Y, Takasaki Y, Soda H, Hasegawa H, et al. Impact of p53 aberration on the progression of Adult T-cell leukemia/lymphoma. Cancer Lett. 2006;234:249–55. DOI: 10.1016/j.canlet.2005.03.039
Kataoka K, Iwanaga M, Yasunaga J-I, Nagata Y, Kitanaka A, Kameda T, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131:215–25. DOI: 10.1182/blood-2017-01-761874
Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, et al. Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol J Am Soc Clin Oncol. 2017;35:2683–91. DOI: 10.1200/JCO.2016.71.8585
Rosewick N, Durkin K, Artesi M, Marçais A, Hahaut V, Griebel P, et al. Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis. Nat Commun. 2017;8:15264. DOI: 10.1038/ncomms15264
Artesi M, Marçais A, Durkin K, Rosewick N, Hahaut V, Suarez F, et al. Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality. Leukemia. 2017;31:2532–5. DOI: 10.1038/leu.2017.260
Shao W, Shan J, Kearney MF, Wu X, Maldarelli F, Mellors JW, et al. Retrovirus integration database (RID): a public database for retroviral insertion sites into host genomes. Retrovirology. 2016;13:47. DOI: 10.1186/s12977-016-0277-6
Marçais A, Waast L, Bruneau J, Hanssens K, Asnafi V, Gaulard P, et al. Adult T cell leukemia aggressiveness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. Oncotarget. 2017;8:52256–68. DOI: 10.18632/oncotarget.13665
Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–10. DOI: 10.1038/nature10738
Christen F, Hoyer K, Yoshida K, Hou H-A, Waldhueter N, Heuser M, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019;133:1140–51. DOI: 10.1182/blood-2018-05-852822
Vallois D, Dobay MPD, Morin RD, Lemonnier F, Missiaglia E, Juilland M, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016;128:1490–502. DOI: 10.1182/blood-2016-02-698977
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319:1676–9. DOI: 10.1126/science.1153629
Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20:728–40. DOI: 10.1016/j.ccr.2011.11.006
Mareschal S, Dubois S, Viailly P-J, Bertrand P, Bohers E, Maingonnat C, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2016;55:251–67. DOI: 10.1002/gcc.22328
Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, et al. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018;132:1507–18. DOI: 10.1182/blood-2018-01-824607
Matsuoka M, Jeang K-T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7:270–80. DOI: 10.1038/nrc2111
Matsuoka M, Jeang K-T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30:1379–89. DOI: 10.1038/onc.2010.537
Shih AH, Chung SS, Dolezal EK, Zhang S-J, Abdel-Wahab OI, Park CY, et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013;98:908–12. DOI: 10.3324/haematol.2012.076729
Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374–82.e4. DOI: 10.1016/j.stem.2017.07.010
Mahgoub M, Yasunaga J-I, Iwami S, Nakaoka S, Koizumi Y, Shimura K, et al. Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proc Natl Acad Sci USA. 2018;115:E1269–78. DOI: 10.1073/pnas.1715724115
Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127:2122–30. DOI: 10.1182/blood-2015-07-659144
Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, et al. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia. 2018;32:645–53. DOI: 10.1038/leu.2017.291
Prochazka KT, Pregartner G, Rücker FG, Heitzer E, Pabst G, Wölfler A, et al. Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica. 2019;104:516–23. DOI: 10.3324/haematol.2018.205013
